+612 9045 4394
 
CHECKOUT
Some Pharmaceutical Drugs : IARC Monograph on the Evaluation of Carcinogenic Risks to Humans - International Agency for Research on Cancer

Some Pharmaceutical Drugs

IARC Monograph on the Evaluation of Carcinogenic Risks to Humans

Paperback

Published: 31st December 1996
Ships: 7 to 10 business days
7 to 10 business days
RRP $138.99
$104.50
25%
OFF
or 4 easy payments of $26.13 with Learn more
if ordered within

Evaluates the carcinogenic risk to humans posed by the therapeutic use of thirteen pharmaceutical drugs, including eight benzodiazepines and related compounds used for the treatment of anxiety and as sedatives and anticonvulsants, three triphenylethylene anti-oestrogenic compounds developed for the treatment of breast cancer, and two cholesterol-lowering agents used to treat patients at high risk for cardiovascular disease. Evaluations are based on a critical assessment of all data available for these compounds, including abundant information on pharmacokinetic and pharmacodynamic effects, precise studies of exposure-response relationships, and findings that shed light on mechanisms of carcinogenic action.
The most extensive monograph evaluates the large body of data on tamoxifen, which has been used for almost two decades as the first-line endocrine therapy for postmenopausal women with advanced metastatic breast cancer. Tamoxifen is also used as adjuvant therapy in patients with breast cancer and is being tested for use as a preventive agent. The evaluation found sufficient evidence in humans for the carcinogenicity of tamoxifen in increasing the risk for endometrial cancer, and conclusive evidence that tamoxifen reduces the risk for contralateral breast cancer in women with a previous diagnosis of breast cancer. Evidence for the carcinogenicity of tamoxifen in other organs was judged inadequate.
Of the benzodiazepines, diazepam, which is the most widely prescribed, received the most extensive evaluation. Evidence reviewed suggested lack of carcinogenicity to the breast and inadequate evidence for carcinogenicity at other sites in humans. Diazepam could not be classified as to its carcinogenic risk to humans. Of the remaining benzodiazepines and related compounds, estazolam, prazepam, ripazepam, and temazepam could not be classified as to their carcinogenicity to humans. Oxazepam was classified as possible carcinogenic to humans on the basis of its carcinogenicity to rodents and uncertainty about extrapolation of experimental data to humans. Phenytoin, which has been widely used since the 1930s as an anticonvulsant in the treatment of epilepsy, was classified as possibly carcinogenic to humans.
Of the remaining triphenylethylene anti-oestrogenic drugs developed for the treatment of breast cancer, neither toremifene, which is just being introduced, nor droloxifene, which is under development, could be classified. Likewise, data were judged inadequate for the classification of the two cholesterol-lowering drugs, clofibrate and gemfibrozil.

Note to the Readerp. 1
List of Participantsp. 3
Preamble
Benzodiazepines and related compounds and phenytoinp. 35
Diazepamp. 37
Doxefazepamp. 97
Estazolamp. 105
Oxazepamp. 115
Prazepamp. 143
Ripazepamp. 157
Temazepamp. 161
Phenytoinp. 175
Anti-oestrogenic compoundsp. 239
Droloxifenep. 241
Tamoxifenp. 253
Toremifenep. 367
Hypolipidaemic drugsp. 389
Clofibratep. 391
Gemfibrozilp. 427
Summary of Final Evaluationsp. 445
Glossaryp. 447
Summary Tables of Genetic and Related Effectsp. 451
Activity Profiles for Genetic and Related Effectsp. 467
Supplementary Corrigenda to Volumes 1-65p. 485
Cumulative Index to the Monographs Seriesp. 487
Table of Contents provided by Blackwell. All Rights Reserved.

ISBN: 9789283212669
ISBN-10: 9283212665
Series: IARC Monographs : Book 66
Audience: Professional
Format: Paperback
Language: English
Number Of Pages: 514
Published: 31st December 1996
Publisher: World Health Organization
Country of Publication: CH
Dimensions (cm): 24.0 x 16.0  x 2.6
Weight (kg): 0.09